AUTHORS
Lacramioara Ivanciu, PHd, Caitlin Cevasco, BS2, John M. Michael Gansner, MD, PhD3, Stephen Lombardelli4, Rodney Camire, PhD5, Martina Helena Lundberg Slingsby, PhD6
AFFILIATIONS
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
2 Alnylam Pharmaceuticals, Boston, Massachusetts, United States
3 Alnylam Pharmaceuticals, Boston, Massachusetts, United States
4 Alnylam Pharmaceuticals, Boston, Massachusetts, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
6 Alnylam Pharmaceuticals, Boston, Massachusetts, United States
ABSTRACT
Introduction: Plasminogen (PLG) is synthesized primarily in the liver and, when activated to plasmin, is the principal mediator of fibrinolysis. Hepatic PLG lowering with an N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (PLG-lowering siRNA) is designed to reduce plasmin generation and fibrinolytic activity without altering thrombin generation. Previous studies have demonstrated that hepatic PLG lowering does not increase thrombin generation or thrombotic risk in wild-type mice and rats (Ivanciu et al., 2025 and Cevasco et al., 2025), and that suppression of PLG activation to plasmin does not enhance venous thrombosis (Sang et al., 2025). Additionally, UK biobank analyses have shown that lower levels of PLG are not associated with venous (Sang et al., 2025) or arterial thrombosis (Krohn et al., 2026).
Treatment of patients with von Willebrand disease (VWD) may include administration of plasma-derived factor complexes that contain both von Willebrand factor (VWF) and factor VIII (pdVWF). Such concentrates increase thrombin generation (Rugeri et al., 2007) and have been associated with thromboembolic complications (Franchini, 2006). To assess the thrombotic safety profile of PLG lowering in the setting of factor replacement therapy, we evaluated the effect of a hepatic PLG-lowering siRNA in combination with pdVWF in a provoked model of arterial thrombosis in VWF knockout (VWF-KO) mice.
Methods: A VWF-KO mouse model, which recapitulates severe human VWD, was used to evaluate the thrombotic safety of PLG lowering in the presence or absence of pdVWF replacement therapy. VWF-KO mice received a single subcutaneous injection of either non-targeting control siRNA or PLG-lowering siRNA (0.5 mg/kg). Fourteen days after dosing, animals were subjected to ferric chloride (FeCl3)-induced carotid artery thrombosis. A subset of mice received an intravenous infusion of pdVWF concentrate (75 IU/kg) 3 minutes before vessel injury. Following completion of the study, livers were collected and hepatic PLG mRNA levels were quantified by reverse transcription quantitative PCR (RT-qPCR) to confirm target knockdown.
Results: Treatment of VWF-KO mice with PLG-lowering siRNA resulted in an 84.1% reduction in liver PLG mRNA on Day 14. Following FeCl3-induced carotid artery injury, no vessel occlusion was observed during the 30-minute observation period in VWF-KO mice treated with either PLG-lowering siRNA or non-targeting control siRNA. Administration of pdVWF concentrate in VWF-KO mice treated with non-targeting control siRNA reduced the mean time to vessel occlusion following FeCl3 exposure. PLG lowering did not further alter the mean time to vessel occlusion in VWF-KO mice treated with pdVWF concentrate (mean ± standard deviation in control siRNA 10.9 ± 2.1 min versus PLG-lowering siRNA, 11.4 ± 1.7 min).
Conclusions: Hepatic PLG lowering with a GalNAc-conjugated siRNA did not enhance the pdVWF response in a provoked arterial thrombotic model in VWF-KO mice. These findings suggest that suppression of the fibrinolytic pathway through liver-directed PLG silencing does not augment the arterial thrombotic response associated with pdVWF replacement therapy. Collectively, these data support the continued clinical development of ALN-6400, an investigational RNA interference therapeutic, for the treatment of all types of VWD (NCT07575308).
References:
Cevasco C et al. Blood 2025;146(Supplement 1):3058.
Franchini M. Hematology 2006;11(1):49–52.
Ivanciu L et al. 30th European Hematology Association (EHA) Congress, 2025.
Krohn L et al. International Society on Thrombosis and Hemostasis (ISTH) Congress, 2026.
Rugeri L et al. Haematologica 2007;92(12):1639–46.
Sang Y et al. Blood 2025;146(11):1346–58.
DISCLOSURES
Rodney Camire, PhD: Alnylam - Research Funding; Roche - Patents & Royalties; CSL Behring - Membership on a Board/Advisory Committee; Roche - Membership on a Board/Advisory Committee